Search Results for: f

2024-ASCO-Identification of immune biomarkers in treatment-naive patients with metastatic pancreatic cancer treated with the GSK-3 inhibitor elraglusib (9-ING-41) in combination with gemcitabine/nab-paclitaxel in the 1801 phase 2 study.

Publications /

2024-ASCO-Identification of immune biomarkers in treatment-naive patients with metastatic pancreatic cancer treated with the GSK-3 inhibitor elraglusib (9-ING-41) in combination with gemcitabine/nab-paclitaxel in the 1801 phase 2 study. Read More »

Actuate Therapeutics Files Registration Statement for Initial Public Offering

May 28, 2024 07:00 ET CHICAGO and FORT WORTH, Texas, May 28, 2024 (GLOBE NEWSWIRE) — Actuate Therapeutics, Inc. (“Actuate”) announced today that it has filed a registration statement with the Securities and Exchange Commission for a proposed initial public offering of its common stock. The number of shares to be offered and the price

Actuate Therapeutics Files Registration Statement for Initial Public Offering Read More »

FAQs

FAQs Corporate FAQs Where is Actuate headquartered? Our corporate headquarters is in Fort Worth, Texas How is Actuate stock traded? Our shares are traded on NASDAQ Global Market under the stock symbol ACTU When was Actuate incorporated? Actuate was incorporated on January 16, 2015 When did Actuate go public? Actuate went public on August 13,

FAQs Read More »